Inventor · disambiguated record
James Cardia
Also filed as: CARDIA JAMES
22 granted patents·6 pending applications·693 citations·filing 2009–2022
97Inventor score
Top patents by PatentIndex Score
28 records- 0199US8796443B2Reduced size self-delivering RNAi compoundsKHVOROVA ANASTASIA·Filed 2009·Granted Aug 5, 2014·105 cites·19 claims
- 0298US9938530B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted Apr 10, 2018·25 cites·19 claims
- 0398US9303259B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2013·Granted Apr 5, 2016·46 cites·12 claims
- 0498US9175289B2Reduced size self-delivering RNAi compoundsRXI PHARMACEUTICALS CORP·Filed 2014·Granted Nov 3, 2015·80 cites·17 claims
- 0598US9080171B2Reduced size self-delivering RNAi compoundsKHVOROVA ANASTASIA·Filed 2011·Granted Jul 14, 2015·91 cites·15 claims
- 0698US8664189B2RNA interference in skin indicationsKHVOROVA ANASTASIA·Filed 2009·Granted Mar 4, 2014·60 cites·2 claims
- 0797US10913948B2RNA interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2018·Granted Feb 9, 2021·21 cites·7 claims
- 0897US10774330B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2015·Granted Sep 15, 2020·15 cites·19 claims
- 0997US10662430B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2018·Granted May 26, 2020·14 cites·19 claims
- 1097US9340786B2RNA interference in dermal and fibrotic indicationsKHVOROVA ANASTASIA·Filed 2011·Granted May 17, 2016·49 cites·20 claims
- 1196US10240149B2Reduced size self-delivering RNAi compoundsPHIO PHARM CORP·Filed 2015·Granted Mar 26, 2019·23 cites·21 claims
- 1296US10184124B2RNA interference in ocular indicationsRXI PHARMACEUTICALS CORP·Filed 2015·Granted Jan 22, 2019·23 cites·14 claims
- 1396US10041073B2Reduced size self-delivering RNAi compoundsKHVOROVA ANASTASIA·Filed 2011·Granted Aug 7, 2018·24 cites·24 claims
- 1496US9963702B2RNA interference in dermal and fibrotic indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted May 8, 2018·23 cites·20 claims
- 1595US9095504B2RNA interference in ocular indicationsLIBERTINE LYN·Filed 2011·Granted Aug 4, 2015·50 cites·10 claims
- 1694US11118178B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2019·Granted Sep 14, 2021·8 cites·10 claims
- 1794US10876119B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2018·Granted Dec 29, 2020·7 cites·20 claims
- 1894US10815485B2RNA interference in skin indicationsPHIO PHARM CORP·Filed 2018·Granted Oct 27, 2020·8 cites·5 claims
- 1993US11584933B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2020·Granted Feb 21, 2023·2 cites·20 claims
- 2091US11001845B2Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)PHIO PHARM CORP·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 2186US11021707B2Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAPHIO PHARM CORP·Filed 2016·Granted Jun 1, 2021·7 cites·19 claims
- 2283US11279934B2Methods for treating cancer using nucleic acids targeting MDM2 or MYCNPHIO PHARM CORP·Filed 2015·Granted Mar 22, 2022·5 cites·8 claims
- 2377US2021147849A1Reduced size self-delivering rnai compoundsPHIO PHARM CORP·Filed 2020·Application pending·0 cites
- 2472US2021261968A1Rna interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2021·Application pending·0 cites
- 2557US2024301430A1Chemically modified oligonucleotidesPHIO PHARM CORP·Filed 2022·Application pending·0 cites
- 2655US2023089478A1Chemically modified oligonucleotides with improved systemic deliveryPHIO PHARM CORP·Filed 2020·Application pending·0 cites
- 2750US2023002766A1Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapyPHIO PHARM CORP·Filed 2020·Application pending·0 cites
- 2846US2016304875A1Methods for treatment of wound healing utilizing chemically modified oligonucleotidesRXI PHARMACEUTICALS CORP·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James Cardia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →